Herbert S B Baraf Selected Research

Pegloticase

1/2022	Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
12/2014	Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
1/2014	Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
9/2013	Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
9/2013	Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
11/2011	2011 Recommendations for the diagnosis and management of gout and hyperuricemia.
11/2011	2011 recommendations for the diagnosis and management of gout and hyperuricemia.
8/2011	Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
9/2008	Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Herbert S B Baraf Research Topics

Disease

11	Gout 01/2022 - 09/2008
5	Pain (Aches) 05/2013 - 04/2005
5	Osteoarthritis 02/2012 - 05/2004
3	Rheumatoid Arthritis 01/2021 - 05/2013
3	Knee Osteoarthritis 01/2011 - 05/2004
2	Rheumatic Diseases (Rheumatism) 01/2020 - 01/2007
2	Hypertension (High Blood Pressure) 02/2012 - 02/2007
1	Necrosis 01/2021
1	Disease Progression 09/2018
1	Gouty Arthritis 02/2013
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2012
1	Type 2 Diabetes Mellitus (MODY) 02/2012
1	Arthritis (Polyarthritis) 01/2007
1	Inflammation (Inflammations) 01/2007
1	Ankylosing Spondylitis 04/2005

Drug/Important Bio-Agent (IBA)

9	Pegloticase FDA Link 01/2022 - 09/2008
8	Uric Acid (Urate)IBA 01/2022 - 09/2008
4	Diclofenac (SR 38)FDA LinkGeneric 02/2012 - 02/2007
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2011 - 01/2007
3	EtoricoxibIBA 02/2007 - 04/2005
2	Urate Oxidase (Uricase)IBA 12/2014 - 09/2008
1	Immunologic Factors (Immunomodulators)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Adalimumab (Humira)FDA Link 01/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	GLPG0634IBA 01/2021
1	golimumab FDA Link 09/2018
1	Infliximab (Remicade)FDA Link 09/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2018
1	tocilizumab (atlizumab)FDA Link 05/2013
1	InterleukinsIBA 02/2013
1	Indomethacin (Indometacin)FDA LinkGeneric 02/2013
1	rilonacept FDA Link 02/2013
1	Allopurinol (Remid)FDA LinkGeneric 08/2011
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 09/2008
1	lumiracoxib (prexige)IBA 01/2007
1	Naproxen (Naprosyn)FDA LinkGeneric 04/2005
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2005
1	Nabumetone FDA LinkGeneric 05/2004
1	rofecoxib (Vioxx)FDA Link 05/2004

Therapy/Procedure

8	Therapeutics 01/2022 - 08/2011
1	Immunomodulation 01/2022